The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Relmada Therapeutics Inc shares valued at $153,707 were purchased by TRAVERSA SERGIO on Sep 11 ’24. At $2.99 per share, TRAVERSA SERGIO acquired 51,407 shares. The insider’s holdings grew to 384,024 shares worth approximately $0.14 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, TRAVERSA SERGIO purchased 55,579 shares, netting a total of over 150,619 in proceeds. Following the buying of shares at $2.71 each, the insider now holds 299,603 shares.
Before that, TRAVERSA SERGIO had added 33,014 shares to its account. In a trade valued at $90,788, the Chief Executive Officer bought Relmada Therapeutics Inc shares for $2.75 each. Upon closing the transaction, the insider’s holdings increased to 33,014 shares, worth approximately $0.12 million.
As published in a research note from Mizuho on December 05, 2024, Relmada Therapeutics Inc [RLMD] has been rated down from an Outperform to a Neutral and the price target has been revised to $1 from $23. Analysts at Jefferies upgraded the stock from ‘”a Hold”‘ to ‘”a Buy”‘ outlook in a report released in mid September. As of June 05, 2024, Goldman has decreased its “Neutral” rating to a “Sell” for RLMD. Earlier on October 14, 2022, Truist downgraded its rating. Their new recommendation was “a Hold” for RLMD stock which previously was a “a Buy”.
Analyzing RLMD Stock Performance
During the last five days, there has been a drop of approximately -2.60%. Over the course of the year, Relmada Therapeutics Inc shares have dropped approximately -91.49%. Shares of the company reached a 52-week high of $7.2225 on 03/04/24 and a 52-week low of $0.3416 on 12/19/24. A 50-day SMA is recorded $2.4109, while a 200-day SMA reached $3.2742. Nevertheless, trading volume fell to 0.61 million shares from 0.54 million shares the previous day.
Support And Resistance Levels for Relmada Therapeutics Inc (RLMD)
According to the 24-hour chart, there is a support level at 0.3463, which, if violated, would cause prices to drop to 0.3311. In the upper region, resistance lies at 0.3733. The next price resistance is at 0.3851. RSI (Relative Strength Index) is 17.53 on the 14-day chart, showing oversold technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.0299, which suggests the price will decrease in the coming days. Percent R is at 93.36%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.
